Isomaltose: A Comprehensive Reference
1. Identity: Chemical and Physical Characterization
1.1 Chemical Names and Structure
Isomaltose, chemically known as 6-O-α-D-glucopyranosyl-D-glucopyranose, is a disaccharide composed of two glucose molecules connected by an α-1,6-glycosidic bond. It is a disaccharide similar to maltose, but with a α-(1→6)-linkage instead of the α-(1→4)-linkage; both sugars are dimers of glucose, which is a pyranose sugar. Isomaltose is a reducing sugar.
This bond distinguishes isomaltose from regular maltose, which has an alpha-1,4-glycosidic bond between its glucose molecules. Chemically, it closely resembles maltose; however, the unique alpha-1,6 linkage differentiates it from its more common counterpart, and this structural variance leads to distinct biochemical properties, applications, and how our bodies process it when compared to maltose.
1.2 Physical Properties
Isomaltose is a disaccharide with a chemical formula of C₁₂H₂₂O₁₁ and is comprised of two glucose units. It has a molar mass of 342.30 g·mol⁻¹. Its melting point is 98–160 °C. It is soluble in water and a fermentable sugar.
1.3 Relationship to Isomaltooligosaccharides (IMOs) and Related Compounds
Isomaltooligosaccharides (IMOs) are glucose oligomers with α-D-(1,6)-linkages, and include isomaltose, panose, isomaltotriose, isomaltotetraose, isomaltopentaose, nigerose, kojibiose, and higher branched oligosaccharides. Isomaltose, one of the α(1,6)-linked disaccharide components of IMO, has been identified as a natural constituent of honey and, although chemically related, it is not itself an IMO.
Isomaltose should not be confused with two closely named but chemically distinct compounds. Isomaltulose and isomaltose are both disaccharide carbohydrates. Isomaltulose, though, is a disaccharide derived from sucrose, while isomaltose is a disaccharide derived from maltose. Isomaltulose and isomaltose have a similar chemical bonding in that a glycosidic bond connects C-1 and C-6 of the two monosaccharide constituents; however, in isomaltose the two monosaccharides are two glucose units, whereas in isomaltulose they are one glucose and one fructose. Similarly, isomalt is a distinct compound: a sugar alcohol derived from isomaltulose, widely used as a reduced-calorie sweetener in sugar-free products such as chewing gums and hard candies.
2. Natural Sources and Occurrence
2.1 Biological Origins
Isomaltose is a naturally occurring disaccharide formed during the breakdown of starch. It is primarily formed during the enzymatic breakdown of starch and glycogen by amylase enzymes, as well as during the industrial production of isomaltose syrups.
Isomaltose consists of two glucose units linked by an α(1→6) glycosidic bond, is derived from starch or glycogen digestion, and is hydrolyzed by isomaltase in the intestinal tract.
2.2 Food Sources
It is found in foods such as honey and beer and is digested in the small intestine by the enzyme isomaltase. The disaccharide isomaltose is also present in rice miso, soy sauce, and sake. More broadly, in fermented foods such as miso, sake, soy sauce, beer, and honey, minimal concentrations of naturally occurring IMOs — including isomaltose — can be observed.
Isomaltose is also a product of glucose caramelization: isomaltose is produced when high maltose syrup is treated with the enzyme transglucosidase (TG) and is one of the major components in the mixture known as isomaltooligosaccharide. It is also a product of the caramelization of glucose.
2.3 Commercial Production
Because of the high market demand for products containing IMOs, obtaining a sufficient supply of naturally occurring IMOs for commercial use is not economically feasible. Consequently, IMOs are being commercially produced through the enzymatic modification of starch. For manufacturing IMO on a commercial scale, food industries use starch processed from cereal crops like wheat, barley, pulses (peas, beans, lentils), oats, tapioca, rice, potato, and others.
Transglucosylation and condensation reactions catalyzed by microbial α-glucosidases can convert glucose-containing syrups from starch to a mixture with a high percentage of α-(1→6)-linked oligosaccharides. In order to convert these molecules into functional and low-caloric molecules, α-1,4 linkages are enzymatically converted into α-1,6 linkages, thus forming IMO. This step is achieved by the addition of transglucosidase, which converts maltooligosaccharides into IMO.
IMO is a sweet-tasting, high-density syrup which can be spray-dried into powder form. Commercially available IMO preparations are described as a colorless or light yellow, transparent syrup.
3. Traditional and Historical Use
3.1 Honey as a Historical Vehicle
Honey is a sweet food that has been consumed since ancient times, originating from nectar and honeydew gathered from various flowers by bees and transformed into a viscous substance. Notably, traditional Chinese medicine (TCM) uses it as a pharmaceutical additive in the preparation of crude drugs derived from medicinal plants. The Chinese Pharmacopoeia described "stir-baking with honey" as the preparation method of crude drugs.
Isomaltose, as a constituent of honey, was thus consumed within this ancient tradition without being recognized as a discrete compound. Traditional Chinese medicine uses honey as a pharmaceutical additive in the preparation of crude drugs derived from medicinal plants, and the Chinese Pharmacopoeia described "stir-baking with honey" as the preparation method of crude drugs. The role of heat-processed honey in TCM is directly relevant to isomaltose, as discussed further in Section 6.4.
3.2 Fermented Foods in East Asian Tradition
IMOs are normal components of the human diet and occur naturally in many fermented foods, including rice miso, soy sauce, and sake. Japanese sake is a traditional rice wine beverage. During the process of brewing sake, the starch in rice is saccharified by various enzymes produced by the koji mold, Aspergillus oryzae, and the resultant glucose is fermented to ethanol by the sake yeast, Saccharomyces cerevisiae. Sake brewed with certain yeast strains is sweet owing to the high content of isomaltose. Although the presence of isomaltose was not historically identified as a specific ingredient, its occurrence in these ancient fermented preparations means that populations consuming these foods — particularly in Japan, China, and Korea — have had sustained dietary exposure to isomaltose over centuries.
Isomalto-oligosaccharides are a normal part of the human diet and occur naturally in fermented foods such as fermented sourdough breads and kimchi. These foods have long histories of use in Europe and Korea, respectively, meaning isomaltose has been part of traditional dietary patterns in multiple cultures.
3.3 Historical Use in Food Technology
Japanese food technology has historically used isomaltose-containing preparations in a wide array of traditional condiments and foods. Isomaltose and high isomaltose content products can be used in food products such as soy sauces, miso, moromi (a refined sake), hishio (a refined soy sauce), furikake (a seasoned fish meal), mayonnaises, dressings, vinegars, sanbai-zu (a sauce of sugar, soy sauce, and vinegar), and various Japanese seasonings and sauces.
4. Key Constituents, Active Compounds, and Mechanisms of Action
4.1 The Disaccharide Itself
Isomaltose is itself the primary active molecule of interest. Its core biochemical identity — two glucose units joined by an α-1,6-glycosidic bond — underlies all of its physiological properties. Like other carbohydrates, isomaltose is used as an energy source by our bodies. It is broken down in the small intestine into separate glucose molecules, which are absorbed into the bloodstream and transported to cells for energy production. It contains the same amount of energy (kilojoules/calories) as regular table sugar (sucrose).
4.2 Enzymatic Digestion and the Sucrase-Isomaltase Complex
The primary enzyme responsible for isomaltose digestion is sucrase-isomaltase (SI), a brush-border glycoprotein located in the small intestinal epithelium. The symptoms of sucrase-isomaltase deficiency are the consequence of absent or drastically reduced enzymatic activities of sucrase and isomaltase, the components of the intestinal integral membrane glycoprotein sucrase-isomaltase (SI).
Human digestive enzymes such as isomaltase and maltase/glucoamylase partially hydrolyze IMOs. The manufacturing process determines the degree of polymerization (DP) and α-(1→4):α-(1→6) linkage ratio in IMOs and the digestibility by brush border enzymes in the small intestine. IMOs that contain a component with higher DP and α-(1→6) linkages are less digestible by human digestive enzymes.
4.3 Fermentation in the Colon and Short-Chain Fatty Acid Production
Those indigestible IMO fractions that escape small intestinal hydrolysis enter the colon and are metabolized by gut microbiota to produce short-chain fatty acids (SCFAs), which are largely responsible for the beneficial effects of fibers. IMOs exhibit prebiotic activity by promoting the growth of beneficial gut microbiota and the production of SCFAs.
The degree to which isomaltose itself — as a disaccharide (DP2) — reaches the colon intact is contested. A recent study demonstrated that IMOs are fully hydrolyzed by mammalian α-glucosidases at a slow pace, suggesting the recharacterization of IMOs from prebiotic or colon-health-promoting substances to slowly digestible carbohydrates.
4.4 Heat-Induced Polymerization and Immunomodulatory Mechanism
Although isomaltose does not exert any pharmacological actions on the immune system in its native form, heat processing produces immunostimulatory activity, with the best conditions being at 180°C for 60 min or 200°C for 15–30 min. Maltose, sucrose, turanose, and trehalose did not exhibit any activity when heated at 180°C for 60 min, indicating that the glucose groups with α(1→6)-binding in the isomaltose molecule play important roles in its activity when oxidatively polymerized by heat.
The stimulating activity of heated isomaltose was inhibited by a toll-like receptor 4 (TLR4) inhibitor, suggesting that heated isomaltose activates TLR4 to induce G-CSF. By size-exclusion HPLC analysis, the average molecular weight of heated isomaltose was 790 kDa.
5. Scientific Evidence by Area of Use
5.1 Gastrointestinal Health and Prebiotic Activity
Prebiotic Evidence in Humans: In a clinical study, older men who were fed a diet supplemented with 10 g of active IMOs for 30 days showed significantly increased concentrations of fecal acetate and propionate. This represents one of the better-characterized human studies supporting a prebiotic-type response.
IMOs are partially digested in the human body by brush border enzymes, including maltase/glucoamylase and isomaltase, while the undigested oligosaccharides get fermented in the large intestines, leading to beneficial gastrointestinal effects and prebiotic properties. However, the extent of this partial digestion varies considerably by product composition. Isomaltooligosaccharides (IMOs) are enzymatically synthesized oligosaccharides that have potential prebiotic effects. Five IMO substrates with 2–16 degrees of polymerization (DP) were studied for their fermentation capacities using human microbiomes in an in vitro batch fermentation model. Eleven fecal slurries belonging to three enterotypes, including the Bacteroides-, Prevotella-, and Mixed-type, exhibited different degradation rates for long chain IMOs (DP 7 to 16).
In Vitro Microbiome Evidence: In an in vitro study comparing five prebiotics, IMO stimulated Lachnospiraceae and Faecalibacterium. Pectin, IMO, and inulin enhanced butyrate levels. Previous studies on related isomalto/malto-polysaccharides (IMMPs) showed an increase in total bacteria, especially lactobacilli, and higher production of short-chain fatty acids when IMMPs were fed to rats or used during in vitro fermentation. Metatranscriptomics was used to investigate how IMMPs with different amounts of α-(1→6) glycosidic linkages affected microbial function during incubation with human fecal inoculum.
Conflicting Digestibility Evidence: A significant caveat exists regarding the digestibility — and thus the prebiotic potential — of isomaltose and lower-DP IMO preparations. Although IMOs are promoted as prebiotic fiber in Asia, there is conflicting evidence on their digestibility with high caloric value as shown in rat and human studies. In clinical studies, BIOLIGO™ IMOs were well-tolerated as demonstrated by the lack of adverse gastrointestinal symptoms, but they had no significant effect on breath hydrogen (an indicator of fermentability). Additionally, these IMOs behaved as caloric sweeteners based on the glycemic and insulinemic response in healthy adults. This is especially relevant for isomaltose itself (DP2), which is the most readily hydrolyzed member of the IMO series.
Intestinal Barrier Function (Animal/Cell Evidence): Supplementation with IMO normalizes intestinal microbiota composition, reduces intestinal permeability, enhances short-chain fatty acid (SCFA) production, and strengthens intestinal tight junctions. These findings are from animal and in vitro models; robust human evidence for these specific endpoints is not yet established.
Constipation (Clinical): IMOs are commonly used in clinical settings at 10 g/day for 4 weeks in Asian countries. The clinical study in elderly men noted above (10 g/day for 30 days) documents increased fecal SCFA production, but direct human evidence specifically on bowel frequency for isomaltose as an isolated compound is limited.
Evidence Strength: For gut microbiota modulation, the evidence consists largely of in vitro batch fermentation studies and one or two small human studies using IMO mixtures, not pure isomaltose. Evidence is preliminary. The question of whether isomaltose at DP2 survives small intestinal digestion to reach the colon remains under active debate in the literature.
5.2 Glycemic Control and Metabolic Health
IMO as a Lower-Glycemic Carbohydrate Source: Some small-scale clinical studies and animal experiments have investigated the effects of IMO on glycemic control. These studies suggest that IMO consumption results in a lower postprandial blood glucose spike and may modestly improve insulin sensitivity. For example, a few human trials have reported that IMO has a lower glycemic index and insulinemic index than maltose or glucose.
Clinical Glycemic Studies with IMO Mixtures: Two randomized, double-blind, placebo-controlled, cross-over human studies were conducted. In the first study (n = 26), participants' breath hydrogen over 24 h, gastrointestinal tolerance, and glycemic and insulinemic response to BIOLIGO™ IL5040 isomaltooligosaccharide were measured. In another study (n = 10), participants' two-hour post-prandial glycemic response to BIOLIGO™ IL5040 and BIOLIGO™ IL7010 isomaltooligosaccharides was measured compared to dextrose (control). Both IMO preparations dose-matched for 50 g total carbohydrates showed similar glycemic response compared to dextrose. Though the incremental area under the curve (iAUC) for venous blood glucose was significantly lower than dextrose beyond 2 h, venous insulin response showed no significant change compared to the control.
Paradoxical Hyperglycemic Observations: A complicating finding from one study is that IMO exhibited a hyperglycemic effect compared to dextrose, as indicated by a GGE of 1.35 g and an RGI of 27.0 g. The responses to IMO of both active GLP-1 and GIP were similar to that of dextrose. The paradoxical hyperglycemic response despite robust insulin and incretin secretion requires further investigation.
A survey of commercially available IMO products in the US indicated that the digestibility and potential glycemic impact of these ingredients were inconsistent with product labels, including soluble fiber content and glycemic response.
Lipid Profiles (Clinical): A clinical trial showed that the daily consumption of IMO-fortified cookies over 4 weeks reduced the levels of cholesterol and triglycerides and decreased cardiac risk ratio scores. Similarly, in another clinical trial, treatment with 30 g of IMOs for 4 weeks significantly reduced total cholesterol and triglyceride levels in patients requiring hemodialysis.
Animal Models — Obesity and Metabolic Syndrome: High-fat diet-induced obesity models have shown that IMOs, administered alone or in combination with other compounds, exhibit potent anti-obesity effects, making them promising agents in the treatment of obesity and its associated complications. Moreover, IMOs exhibit preventive effects against HFD-induced metabolic dysfunction by modulating gut microbiota and short-chain fatty acid levels. These findings are preclinical and have not been replicated in controlled human trials with pure isomaltose.
Evidence Strength: The glycemic effects of IMO mixtures in humans are genuinely mixed. Some studies show modest reductions in postprandial blood glucose compared to standard sugars; others document high glycemic responses comparable to glucose itself. The overall quality, size, and duration of clinical trials remain limited, and most studies have focused on healthy individuals rather than those with established diabetes. Evidence for the lipid-lowering effects is preliminary, from small trials.
5.3 Exercise Performance and Sports Nutrition
Isomaltulose (the closely related compound) in Exercise: Much of the human research in the exercise domain has been conducted using isomaltulose (Palatinose™) rather than isomaltose itself. Isomaltulose ingestion led to lower baseline postprandial concentrations of glucose, insulin, and GIP compared to maltodextrin and glucose. Consequently, blood glucose fluctuations were lower during treadmill running after isomaltulose ingestion, while no between-condition differences were observed for carbohydrate and fat oxidation rates, treadmill running performance, and gastrointestinal discomfort.
Further research is required to provide specific guidelines on supplementing isomaltulose in performance and health settings. Evidence specifically for isomaltose in exercise settings is not established in the peer-reviewed literature; researchers have consistently used isomaltulose as the intervention compound in this context.
5.4 Inflammatory Bowel Disease and Colitis (Animal Evidence Only)
IMOs can reduce IBD and alleviate hyperlipidemia, as indicated by the reduced histological colitis scores and improved lipid profiles observed in clinical trials and animal studies. More specifically at the animal level, the synbiotic mix of IMOs and probiotics was more potent in decreasing TNF-α and lipocalin levels, increasing anti-inflammatory markers such as interleukin-10 and interleukin-22, and improving short-chain fatty acid levels in the cecum content. Animal studies are an important initial step in understanding the safety and efficacy of IMOs, while clinical trials are needed to substantiate their use in humans.
5.5 Colorectal Cancer (Animal Evidence Only)
In animal studies, dietary intake of IMOs attenuated the intestinal inflammatory response, improved the intestinal microecological environment, and slowed the development of DMH-induced early colorectal cancer in rats. This work provides a theoretical basis and technical support for the clinical prevention or treatment of colorectal cancer with prebiotics. In the DMH+IMO-treated group, there was increased abundance of probiotics (Lactobacillus) and decreased abundance of colorectal cancer marker bacteria (Fusobacterium). The key variations in fecal metabolites included decreased levels of glucose, bile acids, and amino acids. No human clinical evidence has been established for colorectal cancer prevention with isomaltose or IMOs.
5.6 Immunomodulation (Cell Line and In Vitro Evidence)
Isomaltose was found to be the primary component in honey when heated to oversee the significant induction of G-CSF secretion from intestinal epithelial cells, making it a useful marker ingredient of honey products suitable for application in TCM. In this study, the induction of G-CSF secretion by heated isomaltose was significantly inhibited by sparstolonin B (an antagonist of both TLR2 and TLR4), suggesting that heated isomaltose might enhance G-CSF secretion by activating at least the TLR4 signaling pathway.
Since G-CSF is clinically used for cancer patients to accelerate their recovery from neutropenia following chemotherapy or accompanied with aplastic anemia, these findings indicate that honey containing a high level of isomaltose could improve immunosuppressive conditions when honey is heated, and that heated isomaltose might be of potential therapeutic use in patients with compromised immunity caused by chemotherapeutic agents. These findings are from intestinal epithelial cell line experiments; no human clinical evidence exists for this application.
5.7 Dental Health
Animal studies describe IMO as a multifunctional molecule which exerts positive effects on digestive health; it acts as a prebiotic, decreases flatulence, has a low glycemic index, and prevents dental caries in animals. Notably, this dental benefit has been more robustly documented for isomaltulose in human studies, where in comparison with sucrose and most other carbohydrates, isomaltulose is not a significant substrate for oral bacteria. Consequently, acid production from isomaltulose in the mouth is too slow to promote tooth decay. Evidence for dental caries prevention specific to isomaltose in humans is not established.
5.8 Mineral Absorption (Animal Evidence)
A balance study was carried out to examine the effects of isomaltulose, lactose, isomalt, and isomaltulose-based oligomers (IBOs) on mineral (calcium, magnesium, phosphorus, and iron) absorption and retention in rats. The relevance of these findings to human mineral nutrition from isomaltose specifically has not been clinically validated.
6. Body Systems Associated with Isomaltose
- Gastrointestinal System: Isomaltose is digested in the small intestine by the brush-border enzyme sucrase-isomaltase; higher-DP IMO fractions may reach the colon and undergo fermentation. Associated with intestinal microbiota modulation, SCFA production, and intestinal barrier integrity in preclinical models.
- Metabolic and Endocrine Systems: Absorbed glucose from isomaltose hydrolysis enters the portal circulation and is subject to insulin-mediated regulation. IMO preparations have been studied for effects on postprandial blood glucose, insulin secretion, GLP-1, and GIP responses.
- Immune System: In vitro and cell line evidence links heat-processed isomaltose to G-CSF secretion via TLR4 signaling in intestinal epithelial cells.
- Cardiovascular System: Preliminary clinical evidence associates IMO consumption with reductions in total cholesterol and triglycerides, attributable at least partly to gut microbiota-mediated SCFA production.
- Oral Health: IMO preparations are associated with reduced acid production by oral bacteria in animal studies.
7. Dosage Forms and Reported Dosages
IMO is a sweet-tasting, high-density syrup which can be spray-dried into powder form. Commercial preparations thus exist in both liquid (syrup) and solid (powder) forms, and are incorporated into functional foods, beverages, nutrition bars, and dietary supplement capsules and tablets.
Specific dosages reported in human clinical studies include:
- In a clinical study in older men, 10 g of active IMOs per day for 30 days significantly increased concentrations of fecal acetate and propionate.
- In Study 1 of a randomized, double-blinded, placebo-controlled crossover trial, 26 healthy adults were assigned to either BIOLIGO™ IL5040 IMO (68.46 g) or dextrose (54.77 g) mixed in 237 mL of water, with both matched for 50 g total carbohydrates.
- In one clinical trial, treatment with 30 g of IMOs for 4 weeks significantly reduced total cholesterol and triglyceride levels in patients requiring hemodialysis.
- IMOs are commonly used in clinical settings at 10 g/day for 4 weeks.
It bears emphasis that these dosages refer to IMO mixture preparations — which include isomaltose among multiple components — rather than pure isolated isomaltose. No standardized clinical dosing regimen for pure isomaltose as a dietary supplement has been established in the peer-reviewed literature.
8. Safety Considerations
8.1 General Tolerability in Healthy Individuals
For healthy individuals with normal isomaltase activity, isomaltose is efficiently digested and metabolized without any adverse effects. There is no evidence of adverse effects in healthy humans at doses up to 40 g.
BIOLIGO™ IMOs are well-tolerated as demonstrated by the lack of adverse gastrointestinal symptoms and they have no effect on breath hydrogen (an indicator of fermentability).
8.2 Acute Toxicity
An acute oral toxicity study in male Wistar rats administered IMO by gavage with doses up to 44 g/kg body weight found the oral LD50 value of IMO was estimated to be more than 44.0 g/kg bw. This indicates an extremely low acute toxicity profile.
8.3 Congenital Sucrase-Isomaltase Deficiency (CSID)
The most significant and well-documented safety concern associated with isomaltose is its maldigestion in individuals with sucrase-isomaltase deficiency. Congenital sucrase-isomaltase (SI) deficiency is a rare genetic condition characterized by a deficiency in the brush-border SI enzyme, resulting in an inability to metabolize sucrose and starches. Congenital sucrase-isomaltase deficiency (CSID) is an autosomal recessive human intestinal disorder that is clinically characterized by fermentative diarrhea, abdominal pain, and cramps upon ingestion of sugar.
Genetic sucrase-isomaltase deficiency (GSID) is an inherited deficiency in the ability to digest sucrose and potentially starch due to mutations in the sucrase-isomaltase (SI) gene. Congenital sucrase-isomaltase deficiency is historically considered to be a rare condition affecting infants with chronic diarrhea as exposure to dietary sucrose begins. Growing evidence suggests that individuals with SI variants may present later in life, with symptoms overlapping with those of irritable bowel syndrome.
Mutations in the SI gene result in abnormal synthesis and/or incorrect transport of the SI enzyme. Patients with CSID generally have reduced sucrase activity, but levels of isomaltase activity range from absent to almost normal.
Congenital Sucrase-Isomaltase deficiency is a rare metabolic disorder characterized by the inability of the individual to digest certain sugars due to a deficiency of sucrase-isomaltase. Without this enzyme, isomaltose, sucrose, and isomaltulose are unabsorbed and thereby act as osmotic laxatives.
Typical presenting symptoms were watery diarrhea, abdominal pain and bloating, sometimes noticeably worse after ingestion of fruit. Currently, disaccharidase assay on duodenal mucosal tissue homogenates is the gold standard in diagnosing SI deficiency.
Individuals with sucrase-isomaltase deficiency should limit their intake of starch-rich foods and isomaltose-containing products. It is anticipated that IMO will be poorly tolerated by individuals with congenital or acquired sucrase-isomaltase deficiency.
8.4 Glycemic Considerations in Diabetes
As noted in Section 5.2, the glycemic response to IMO preparations — which contain isomaltose as a constituent — is inconsistent across studies, with some demonstrating near-equivalent blood glucose elevation to dextrose. These IMOs are caloric sweeteners based on the glycemic and insulinemic response in healthy adults. This is a material safety consideration for individuals managing blood glucose and should be taken into account when assessing isomaltose-containing products marketed with low-glycemic claims.
8.5 Product Labeling Discrepancies
A survey of commercially available IMO products in the US indicated that the digestibility and potential glycemic impact of these ingredients were inconsistent with product labels, including soluble fiber content and glycemic response. This reflects a recognized issue in the dietary supplement industry, where IMO preparations have sometimes been labeled as dietary fiber or low-calorie ingredients despite evidence of substantial digestibility in human brush-border enzymes.
8.6 Gastrointestinal Tolerance at Higher Doses
Further studies are needed to determine the postprandial effects of larger doses of IMO on blood glucose, gastrointestinal tolerance, and gut microbiota over longer durations. At very high intake levels, as is typical with fermentable oligosaccharides more broadly, flatulence and osmotic gastrointestinal discomfort may occur, though specific dose thresholds for isomaltose-induced symptoms in humans have not been precisely defined in the peer-reviewed literature.
9. Summary of Evidence Strength
- Chemical identity and basic metabolism: Well-established. Isomaltose is a defined chemical entity with thoroughly characterized enzymatic digestion pathways.
- Prebiotic / gut microbiota effects: Preliminary to moderate; supported by in vitro, animal, and a small number of human studies using IMO mixtures. Evidence specific to pure isomaltose at DP2 is limited.
- Glycemic management: Mixed and contested. Evidence ranges from modest blood glucose lowering to near-equivalent glycemia compared to dextrose, depending on preparation and study design.
- Lipid-lowering: Preliminary; small human trials with IMO mixtures show modest effects.
- Anti-inflammatory / IBD: Largely animal and in vitro; no robust human RCT evidence.
- Immunomodulation (G-CSF induction): Cell line evidence only; not yet validated in animal or human studies.
- Colorectal cancer prevention: Animal model data only; no human evidence.
- CSID: Well-established clinical disorder directly relevant to isomaltose intolerance.
References
Go back